scholarly journals Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe

Oncotarget ◽  
2017 ◽  
Vol 8 (45) ◽  
pp. 79731-79741 ◽  
Author(s):  
Jürgen C. Becker ◽  
Eva Lorenz ◽  
Selma Ugurel ◽  
Thomas K. Eigentler ◽  
Felix Kiecker ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Treatment Outcomes ◽  
Merkel Cell Carcinoma ◽  
Real World ◽  
Second Line ◽  
Merkel Cell ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA

2017 ◽  
Vol 13 (19) ◽  
pp. 1699-1710 ◽  
Author(s):  
C Lance Cowey ◽  
Lisa Mahnke ◽  
Janet Espirito ◽  
Christoph Helwig ◽  
Dina Oksen ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Treatment Outcomes ◽  
Merkel Cell Carcinoma ◽  
Real World ◽  
Merkel Cell ◽  
The Usa

scholarly journals Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel

2021 ◽  
Author(s):  
Charles Lance Cowey ◽  
Frank X Liu ◽  
Ruth Kim ◽  
Marley Boyd ◽  
Nicole Fulcher ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Merkel Cell Carcinoma ◽  
Real World ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Response Rates ◽  
Merkel Cell ◽  
First Line ◽  
The Usa

Aim: To assess clinical outcomes in patients with locally advanced (la) or metastatic (m) Merkel cell carcinoma (MCC) initiating first-line (1L) avelumab in a USA community oncology setting. Materials & methods: Adults with laMCC or mMCC initiating 1L avelumab were identified from The US Oncology Network electronic health record database and chart review. Results: Median overall survival and progression-free survival were not reached in laMCC (n = 9) vs 20.2 and 10.0 months in mMCC (n = 19); response rates were similar (66.7% vs 63.2%). Conclusion: This is the first study to show clinical benefit in patients with laMCC receiving 1L avelumab in a US real-world setting. Response rates in patients with mMCC were consistent with pivotal trials.

scholarly journals PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA

2019 ◽  
Vol 22 ◽  
pp. S511
Author(s):  
N.A. Avxentyev ◽  
M. Frolov ◽  
A. Makarov ◽  
R. Palencia ◽  
O.V. Kudelya ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Merkel Cell

Methotrexate, Vinblastine, Epidoxorubicin, and Bleomycin as Second-Line Chemotherapy for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

ORL ◽  
1994 ◽  
Vol 56 (5) ◽  
pp. 279-282 ◽  
Author(s):  
Vittorio Gebbia ◽  
Roberto Valenza ◽  
Antonio Testa ◽  
Nicolò Borsellino ◽  
Giuseppe Cannata ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Metastatic Squamous Cell Carcinoma ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document